Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Tax Provisions (2017 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Tax Provisions for 9 consecutive years, with -$67000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions rose 38.53% year-over-year to -$67000.0, compared with a TTM value of -$114000.0 through Dec 2025, down 300.0%, and an annual FY2025 reading of $43000.0, down 24.56% over the prior year.
  • Tax Provisions was -$67000.0 for Q4 2025 at Karyopharm Therapeutics, down from $34000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $149000.0 in Q1 2021 and bottomed at -$121000.0 in Q4 2021.
  • Average Tax Provisions over 5 years is $55111.1, with a median of $69000.0 recorded in 2024.
  • The sharpest move saw Tax Provisions plummeted 295.16% in 2021, then skyrocketed 185.95% in 2022.
  • Year by year, Tax Provisions stood at -$121000.0 in 2021, then surged by 185.95% to $104000.0 in 2022, then grew by 2.88% to $107000.0 in 2023, then crashed by 201.87% to -$109000.0 in 2024, then soared by 38.53% to -$67000.0 in 2025.
  • Business Quant data shows Tax Provisions for KPTI at -$67000.0 in Q4 2025, $34000.0 in Q3 2025, and -$109000.0 in Q4 2024.